Noname Launches from Stealth to Eliminate API Security Chaos for Enterprises
15.12.2020 16:00:00 EET | Business Wire | Press release
Noname Security, the enterprise API security company, launched from stealth today with $25 million in funding from Lightspeed, Insight Partners and Cyberstarts. Noname is the only holistic security platform that lets enterprises see and secure managed and unmanaged APIs exposed by the organization, consumed by the organization or used internally, thereby eliminating the API security blind spots that exist in most businesses today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005410/en/
Pictured (left to right): Noname Security Co-founders Oz Golan and Shay Levi. (Photo: Business Wire)
Digital transformation encourages companies to leverage APIs extensively to grow business and promote innovation. However, many have an underdeveloped API security strategy, which creates a major attack surface. Gartner has stated that "by 2022, API abuses will move from an infrequent to the most-frequent attack vector, resulting in data breaches for enterprise web applications."(*)
Noname provides an agentless security platform that gives enterprises a complete view into the activity and threats in their environment. Frictionless to deploy, Noname integrates with existing IT infrastructure and gives businesses visibility, security, and control over any API, whether on or off the corporate API gateways. With Noname, enterprises are able to gain the productivity benefits of using APIs without sacrificing security.
"Application security has a huge blind spot," said Oz Golan, CEO and co-founder of Noname. "A leaky API on T-Mobile’s website exposed customer data. The US Postal Service API vulnerability exposed personal information of 60 million users of its online service. The fact you cannot place agents on every application server, and you cannot trust network architecture to funnel all APIs through a single gateway, means we need a new approach. We built Noname to give enterprises complete visibility into all APIs in their environment without requiring an agent or relying on API gateways. We can stop APIs from compromising corporate assets, regardless of whether those APIs are managed by IT or not."
"Noname's holistic solution to API security is spot on. The breadth and depth of insights provided while being so easy to deploy is magic," said Joseph Tso, a leading banking CISO.
Founded in 2020, and headquartered in Palo Alto, California, with an office in Tel Aviv, the Noname team is composed of top engineering talent from Israel and experienced Silicon Valley technology leaders. Noname CEO and co-founder Oz Golan was Director of Engineering at NSO. He served with co-founder and CTO Shay Levi in the selective Unit 8200 of the Israeli Defense Forces, whose alumni also founded Check Point, Waze (acquired by Google) and Palo Alto Networks.
Gili Raanan, Cyberstarts founder, was the first to partner with Noname, while Guru Chahal, Partner at Lightspeed Venture Partners, and Thomas Krane, Principal at Insight Partners, joined to close the Series A round.
"The exponential growth of APIs introduces risk that most enterprises are not prepared to handle," said Gili Raanan of Cyberstarts. "Oz and Shay's strong vision combined with their decision to blend top Israeli engineering talent with sales and marketing executives from Cylance, Armis and NSO set them up for success."
"Noname presents a big opportunity to help enterprises navigate the uncharted territory of APIs in their environment," said Guru Chahal of Lightspeed Venture Partners. "We were impressed with how the team has really listened to their customers to deliver what businesses need. Customers especially liked the on-click frictionless deployment for API discovery and stopping unauthorized access to their applications."
"Our investment in Noname represents Insight’s commitment to partnering with the next generation of Israeli software ScaleUps," said Thomas Krane, Principal at Insight Partners. "Noname’s pure-play API security platform delivers on the long-awaited hope for true runtime application security and will enable enterprises to continue their digital transformation without sacrificing security. We are thrilled to partner with Oz, Shay, and the rest of the team to bring the Noname product to the global enterprise community."
To learn more about Noname visit: www.nonamesecurity.com
(*) Gartner, API Security: What You Need to Do to Protect Your APIs, Mark O’Neill, Dionisio Zumerle, et al., 28 August 2019.
About Noname Security
Noname Security eliminates API security blind spots and protects enterprises from data leakage, authorization issues, abuse, misuse and data corruption with no agents and no network modifications. Fortune 500 companies trust Noname's holistic API security platform to see and secure their APIs. Noname is a privately held company headquartered in Palo Alto, California, with an office in Tel Aviv. www.nonamesecurity.com
About Lightspeed Venture Partners
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400 companies globally, including Snap, Nest, Nutanix, AppDynamics, MuleSoft, OYO, Guardant, StitchFix, and GrubHub. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia and Europe. www.lsvp.com
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. www.insightpartners.com
About Cyberstarts
Cyberstarts is a venture capital firm focused on cybersecurity and is backed by successful cybersecurity entrepreneurs. Cyberstarts is a leading platform for amazing teams of entrepreneurs solving the next big pain points in the cybersecurity world. Cyberstarts founder, Gili Raanan, was the first investor in cybersecurity-focused companies like Armis, Adallom, Axis and Fireblocks. www.cyberstarts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005410/en/
Contact information
Noname Security
Shay Levi | shay@nonamesecurity.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom